Something both sides agree on: A bill to prevent late-stage cancer
600,000 people in the U.S. will die of cancer this year.
Cancer is a leading cause of death worldwide, affecting millions of families each year. Evidence consistently shows that early detection significantly improves treatment outcomes, reduces costs and saves lives. Investing in early detection is a critical and cost-effective public health strategy.
Despite this, our healthcare system is still struggling to keep up.
Many Americans, especially those living on fixed incomes, in rural communities or facing already limited access to healthcare, are being diagnosed at later stages of cancer, when outcomes are poorer and treatment much more expensive.
And for too many, the diagnosis arrives not just as a health crisis, but as a financial one. I have worked with too many families who find themselves facing impossible choices — buy groceries for the week or cover their cancer treatments.
Against this backdrop, Congress has a rare and urgent opportunity to act.
Last year, members of the House Committee on Ways and Means shared deeply personal stories of how cancer has touched their lives as they reviewed and unanimously supported the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
So, it should come as no surprise that the act is the first and only health care bill to garner majority support in both the House and Senate. That level of bipartisan consensus is almost unheard of. But the job isn't finished until this bill becomes law.
My organization, the Cancer Support Community, and other nonprofits have seen where the system fails patients. Rural communities, in particular, face significant disparities in access to timely screening and care.
Our data shows that longer travel times to treatment often result in later-stage diagnoses and lower quality of life. Catching cancer early can prevent this, offering patients the opportunity to receive less aggressive (and less expensive) treatment, and most importantly, more time with loved ones.
Yet many cancers still lack reliable screening tools. Expanding investment in early detection is not only a medical imperative, it's an economic one.
The earlier cancer is found, the less it costs to treat and the better the chances of survival. One estimate suggests that the preventative cancer screenings we do have saved the U.S. a cumulative $6.5 trillion over the last 25 years.
The Nancy Gardner Sewell Act would modernize Medicare to allow for coverage of cutting-edge screening technologies that can detect dozens of cancers through a simple blood test.
This policy would mark a turning point in the fight against cancer, particularly for older adults who face the highest risk and are often diagnosed in later stages.
The support is overwhelming. More than 550 organizations representing cancer patients, providers, researchers and advocates have urged lawmakers to seize this moment. Congress has already thoroughly vetted this bill and cleared it for passage.
When lawmakers return from their summer break, there will be no better time to get this bill over the finish line.
Everything is ready to go. The support is there. Now is the time for passage.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
15 minutes ago
- Newsweek
Potato Salad Recall Map Shows New Warning Issued in 5 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Hans Kissle is recalling its Red Potato Bliss Salad due to an undeclared wheat allergen discovered in a labeling error. Newsweek reached out to the company for comment via phone on Tuesday night and left a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential of damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. People with a wheat allergy could experience a "serious or life-threatening allergic reaction if they consume these products," the FDA warns. What To Know In the alert, the FDA says that 66 units of the potato salad are being recalled because of the mislabeling issue. The product is packaged in a 16-ounce container that is clear and has a white lid. The product's UPC Code number is 036217673706 and has a use-by date of August 20, 2025. The container says, "Hans Kissle Tri Color Twist Pasta Salad" while the top says, "Hans Kissle Red Bliss Potato Salad," the FDA says. There have been no reported illnesses or adverse reactions as it relates to this recall as of Tuesday, the FDA says. The recalled potato salads were distributed to Stop & Shop retail locations in five states, the alert notes. Below is a map showing the affected states, which include New York, New Jersey, Rhode Island, Connecticut and Massachusetts. What People Are Saying The FDA in the alert, in part: "The recall was initiated after it was discovered that 66 containers of Tricolor Twist Pasta Salad were mislabeled with the incorrect top label. While the front label correctly identifies the product, the top label misrepresents it as Red Bliss Potato Salad. The actual product contains wheat, which is not declared on the top label." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall." It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Consumers are advised to return the recalled product to the original place of purchase for a full refund, the FDA says. People with additional questions may contact the company via phone at 978-556-4500 from 8 a.m. to 5 p.m. ET weekdays.
Fox News
3 hours ago
- Fox News
Biden's doctor thought cognitive tests were 'meaningless,' ex-aide Bruce Reed told investigators
Former White House physician Kevin O'Connor previously dismissed cognitive tests as "meaningless," ex-Biden administration aide Bruce Reed told House investigators on Tuesday, according to a source familiar with the proceedings. Reed, who served as White House deputy chief of staff for policy, is the ninth member of former President Joe Biden's inner circle to sit down with House Oversight Committee lawyers. A source familiar with his interview told Fox News Digital that Reed attributed Biden's disastrous 2024 debate performance against then-candidate Donald Trump to the former president's stutter, a condition that's been well-documented and Biden himself has publicly acknowledged. But his meandering and seemingly tired demeanor on stage with Trump alarmed both Democrats and media pundits, who saw it as a glaring sign of Biden's advanced age. It precipitated both a public and private push by left-wing lawmakers to get Biden to drop out of the race – which he did in July 2024. When asked whether public concerns about Biden's mental acuity were legitimate, however, the source told Fox News Digital that Reed said he believes Americans should not have had any concerns about the ex-president's mental faculties. Reed also told investigators that "the president's communications team anticipated that the issue of a cognitive test would likely be raised" in Biden's interview with ABC News host George Stephanopoulos following the debate. "Mr. Reed further explained that President Biden's physician, Dr. Kevin O'Connor, dismissed cognitive tests as 'meaningless,'" the source said. O'Connor was among the first former White House officials summoned by House investigators, and sat down with them last month after being compelled via subpoena. But his sit-down lasted less than an hour, with the doctor opting to invoke the Fifth Amendment to avoid answering all questions but his name. His lawyers said at the time that was due to concerns about violating doctor-patient confidentiality. In his own interview Tuesday, Reed also defended the Biden 2024 campaign's preference to hold the debate earlier than typical for a presidential cycle, the source said. "During his interview, Mr. Reed stated that the decision to hold the debate early was a deliberate strategy to get ahead of early voting and the Olympics. He emphasized that the campaign's push for the early debate was unrelated to concerns about President Biden's age," the source said. Excerpts of Reed's opening statement to investigators, obtained by Fox News Digital via a second source familiar with the interview, show he emphatically defended Biden's cognitive abilities. "While I can only speak to my own observations, I had the benefit of working with President Biden nearly every day of his presidency. Despite his age, President Biden maintained an unrelenting work ethic, embraced complex policy issues, and approached decisions with diligence and deliberation," Reed said, according to the source. Reed also described Biden as "a demanding boss who routinely grilled staff members on a topic until he reached the limits of our knowledge so he could judge whether to have confidence in our advice," though "that didn't mean he'd take it." "From the first days in the White House to the last, President Biden governed the same way he'd gotten there, by trusting his own values and instincts," Reed said, according to the source. "There is no tougher test than the presidency: President Biden asked tough questions, made tough decisions, and led his country well in challenging times for the nation and the world." Chairman James Comer, R-Ky., is probing whether Biden's senior aides worked to cover up evidence of mental decline in the former president, and whether that meant Biden was not making the final decision on executive matters signed by autopen. Of particular interest to Comer is the myriad of clemency orders Biden signed in the latter half of his presidency, though the former president told The New York Times last month that he was behind every decision. His allies have also dismissed Comer's probe as purely political. Fox News Digital reached out to Reed's counsel and lawyers for O'Connor for comment but did not hear back by press time.
CNBC
5 hours ago
- CNBC
Healthy Returns: Medicare, Medicaid will reportedly pilot covering obesity drugs – a potential win for drugmakers
For once, the Trump administration may be giving some drugmakers a reason to celebrate. The Trump administration is planning to experiment with covering costly weight loss drugs under Medicare and Medicaid, the Washington Post reported on Friday. That plan could expand access to millions of Americans with obesity who can't currently afford Novo Nordisk's Wegovy and Eli Lilly's Zepbound, blockbuster GLP-1 drugs that cost around $1,000 per month before insurance. In a statement to CNBC about the plan, the Department of Health and Human Services said all drug coverages undergo a "cost-benefit review." The Centers for Medicare and Medicaid Services "does not comment on potential models or coverage," the department added. The reported plan – if it ultimately takes effect – would be a huge win for Eli Lilly, Novo Nordisk and many Americans. Spotty insurance coverage of obesity drugs remains the biggest barrier to access for patients – and it's choking broader uptake and revenue growth for the two pharmaceutical giants. Many health plans, including Medicare, cover GLP-1s for treatment of diabetes, but not obesity. Medicaid coverage of obesity drugs is limited and varies by state, according to health policy research organization KFF. But it's important to remember that this plan isn't exactly new. In November, the Biden administration proposed having Medicare and Medicaid cover obesity treatments, which would have extended access to roughly 3.4 million Medicare beneficiaries and about 4 million Medicaid recipients. The proposal was controversial at the time, as it would cost taxpayers as much as $35 billion over the next decade, a congressional analysis found. The Trump administration dropped that proposal in April, but said it could reconsider coverage of those drugs in the future. Let's get into what the newest reported iteration of the plan looks like. Under the Trump administration's reported pilot plan, state Medicaid programs and Medicare Part D plans would be able to voluntarily choose to cover Ozempic, Wegovy, Mounjaro and Zepbound for patients for "weight management" purposes. That's according to several Centers for Medicare and Medicaid Services documents obtained by the Post. The plan is expected to start in April 2026 for Medicaid and January 2027 for Medicare plans, the Post reported. It's unclear how exactly the plan will play out, Jared Holz, Mizuho health care equity strategist, said in a note to clients on Friday. Holz said he expects the government to put some coverage parameters in place related to factors like age, body weight, body mass index and other comorbidities, or coexisting chronic health conditions. He also said the pricing of the drugs will be a "major consideration." Holz said he expects the government to pay less than the current list prices of drugs. But having that coverage would expand access and could help drive higher sales volumes, he noted. Another factor to consider is how much the government is willing to crack down on so-called compounding pharmacies, which are allowed in rare cases to sell cheaper, unapproved versions of GLP-1s. The pharmaceutical industry fiercely opposes those knock-off GLP-1s, as their safety and efficacy aren't vetted by regulators and they are, in some cases, illegally sold at scale. Holz said the industry's complaints to the government about compounded GLP-1s have so far "not been met with a widespread shut-down." But overall, Holz said the Trump administration's reported willingness to consider covering obesity drugs is "a slight positive as far as industry sentiment." It's definitely a breath of fresh air for Eli Lilly, Novo Nordisk and other drugmakers – including Amgen, Roche, AstraZeneca and Pfizer – that are hoping to bring their own obesity drugs to market. The last six months have been anything but smooth for the broader industry: The Trump administration has ratcheted up calls for drugmakers to lower U.S. drug prices, overhauled federal health agencies and could impose sweeping tariffs on pharmaceuticals imported into the country any day now. We'll keep watching to see whether this plan gets implemented, so stay tuned for our coverage! Feel free to send any tips, suggestions, story ideas and data to Annika at After reporting its second straight earnings miss and guidance cut, UnitedHealth Group completed its executive sweep by replacing CFO John Rex. Executives on the earnings call admitted to mis-execution in Medicare Advantage and pledged to get back to profitability and win back investor trust. Nearly two years ago it was CVS Health under pressure, after profits in the company's Aetna health insurance division were torpedoed by low Medicare Advantage Star quality ratings. This week, CVS beat and raised its outlook on the strength of its MA program. CEO David Joyner, now one year into the job, told me he feels good about the turnaround at Aetna and its Medicare business. On top of that, the company saw market share gains in its stores, thanks in part to winning over Rite Aid customers. Humana, similarly, has seen progress on its turnaround, but CFO Celeste Mellet told me that all insurers are grappling with pricing plans for next year amid high medical costs. One big cost driver right now, Mellet told CNBC, is oncology drugs, as some expensive therapies are now being used in combination. The next moment of truth for the Medicare Advantage players will come over the next six weeks – when they'll learn the fate of their Star ratings for 2026 plans. Long-time health-care executive Dr. Marc Harrison has stepped down as CEO of General Catalyst's Health Assurance Transformation Company, or HATCo, and has moved into a strategic advisor role, CNBC has confirmed. The venture capital firm brought in Harrison and announced the formation of HATCo in 2023. In a release at the time, General Catalyst said the company would work closely with health system partners, and that it would eventually acquire and operate its own health system. Months later, HATCo announced its plans to buy Summa Health, a nonprofit integrated health system in northeast Ohio. Under its new structure, Summa would become a for-profit organization, and General Catalyst said it would introduce new tech-enabled solutions that aim to make care more accessible and affordable. Buying a health system is an unprecedented move in the venture industry, and the deal wasn't well received by some members of the Ohio community. Hundreds signed a petition urging Summa to remain a nonprofit and to halt negotiations with HATCo. Ohio Attorney General Dave Yost conditionally approved the deal in June, though he outlined a number of "enforceable commitments" as part of the agreement. HATCo will have to notify the Attorney General of transactions that could trigger antitrust concerns for 10 years after the deal closes, for instance. Harrison went to medical school in the late 1980s and has spent most of his career within health systems, most recently as CEO of Intermountain Healthcare. General Catalyst told CNBC that Harrison will continue to provide the firm's CEO, Hemant Taneja, with clinical insights and will remain connected to its ecosystem in his new role. "It became increasingly clear to both Marc and to us that Marc's role would best be accomplished as a strategic advisor to Hemant Taneja as we bring that ambition and vision to life," a General Catalyst spokesperson said. Daryl Tol, the head of General Catalyst's Health Assurance Ecosystem, was promoted to president of HATCo, the spokesperson said. He will spearhead the firm's day-to-day- work with Summa Health leadership. General Catalyst has also appointed Kate Walsh, the former Massachusetts Secretary of Health and Human Services, to HATCo's board. In addition, she will serve as the chair of the board at Summa Health once the transaction closes. "We are grateful for Marc's leadership and collaboration as co-founder and CEO to help get us to this point in the evolution of HATCo, and we look forward to leveraging his invaluable perspective as we continue to progress," the spokesperson said.
